Introduction
Chronic subdural hematoma (CSH) is one of the most common forms of intracranial hemorrhage.
It is a collection of encapsulated, well-delimited fluid and/or coagulated blood in
several clotting stages located between the dura-mater and the arachnoid mater.[1]
[2]
Chronic subdural hematoma is clinically important because, in most cases, its evolution
without immediate surgical treatment can lead to high morbidity and mortality. Therefore,
early diagnosis and successful surgical drainage are imperative to ensure a complete
recovery.[2]
[3]
Although CSH is a highly frequent and clinically relevant disease, epidemiological
data are still limited in Brazil. The present work aims to describe the epidemiological
aspects of CSH according to the database of the Brazilian Unified Health System (SUS,
in the Portuguese acronym). The following variables were studied from 2008 to the
first half of 2016: admission numbers, hospitalization expenses, health care professional
expenses, mortality rate, and death numbers.
Materials and Methods
Information on the surgical treatment of CSH was obtained from code 04.03.01.03.14
between January 2008 and June 2016; this code is used for issuing hospital admission
authorizations (HAAs) at the Informatics Department of the Unified Health System (DATASUS,
in the Portuguese acronym) virtual database. The present review evaluates admission
numbers, hospitalization expenses, health care professional expenses, mortality rates,
and death numbers during the period studied.
Scientific papers from the past 10 years which were electronically published at the
PubMed, Scielo and LILACS databases were used in the present review. These papers
were retrieved using the following descriptors in Portuguese and in English: epidemiologia/epidemiology and hematoma subdural crônico/chronic subdural hematoma. Initially, 119 papers were found at PubMed, 3 at Scielo, and 71 at LILACS. However,
only 13 papers were used in the present review, since those that did not present epidemiological
information on CSH, such as prevalence and incidence, were excluded.
Results
According to [Table 1] and [Fig. 1], there were 2,389 HAAs in 2008, of which more than half were in the Southeast region
(1,284). Meanwhile, the Northern region had the lowest HAA index, with 101 cases.
The number of HAAs increased over time, with a total number of 4,885 in 2015, and
of 2,453 HAAs in the first half of 2016.
Fig. 1 Number of hospital admission authorizations (HAAs) approved per year for the chronic
subdural hematoma surgical treatment code. *Data from 2016 correspond to the first
semester. Source: DATASUS. Accessed on September 1, 2016.
Table 1
Number of hospital admission authorizations (HAAs) approved per year for the chronic
subdural hematoma surgical treatment code
|
North
|
Northeast
|
Southeast
|
South
|
Central-West
|
Total
|
Population estimate
|
|
2008
|
101
|
289
|
1,284
|
415
|
300
|
2,389
|
189,600,000
|
|
2009
|
169
|
479
|
1,676
|
515
|
403
|
3,242
|
191,480,630
|
|
2010
|
223
|
533
|
1,906
|
599
|
471
|
3,732
|
190,755,799
|
|
2011
|
193
|
601
|
2,060
|
640
|
512
|
4,006
|
–
|
|
2012
|
207
|
645
|
2,127
|
643
|
483
|
4,105
|
193,946,886
|
|
2013
|
230
|
747
|
2,209
|
722
|
484
|
4,392
|
201,032,714
|
|
2014
|
230
|
759
|
2,380
|
768
|
537
|
4,674
|
202,768,562
|
|
2015
|
213
|
808
|
2,540
|
706
|
618
|
4,885
|
204,450,649
|
|
2016*
|
95
|
410
|
1,260
|
392
|
296
|
2,453
|
206,391,315
|
|
Total
|
1,661
|
5,271
|
17,442
|
5,400
|
4,104
|
33,878
|
–
|
|
Average
|
184.55
|
585.66
|
1,938
|
600
|
456
|
–
|
–
|
*Data from 2016 correspond to the first semester. Source: DATASUS/IBGE (http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/qiuf.def). Accessed on September 1, 2016.
[Table 2] shows that hospital expenses also increased over the years. In 2008, the total expense
was of BRL 3,803,093.70 and, in 2015, of BRL 10,319,288.77; the highest value was
reached in the Southeast region, followed by the South and Central-West regions. In
the following years, the Northeast region assumed the 3rd position regarding hospital-specific expenses, with BRL 855,176.35 in 2011, and BRL
1,681,269.55 in 2015.
Table 2
Hospital expenses (in BRL) per year for the chronic subdural hematoma surgical treatment
code
|
North
|
Northeast
|
Southeast
|
South
|
Central-West
|
Total
|
|
2008
|
142,396.23
|
366,680.83
|
1,993,721.28
|
878,814.47
|
421,480.89
|
3,803,093.70
|
|
2009
|
288,533.57
|
605,903.04
|
2,759,078.36
|
1,177,276.80
|
742,875.76
|
5,573,667.53
|
|
2010
|
399,103.93
|
689,638.94
|
3,434,604.02
|
1,405,519.81
|
870,073.75
|
6,798,940.45
|
|
2011
|
356,896.29
|
855,176.35
|
3,840,565.12
|
1,566,255.29
|
834,296.26
|
7,453,189.31
|
|
2012
|
421,962.60
|
1,064,555.36
|
4,293,906.36
|
1,580,971.21
|
811,095.93
|
8,172,491.46
|
|
2013
|
456,460.13
|
1,314,112.97
|
4,435,818.31
|
1,710,917.57
|
844,060.34
|
8,761,369.32
|
|
2014
|
420,430.72
|
1,419,506.18
|
4,902,076.14
|
1,970,913.28
|
1,102,661.80
|
9,815,588.12
|
|
2015
|
466,275.23
|
1,681,269.55
|
5,271,961.14
|
1,760,071.79
|
1,139,711.06
|
10,319,288.77
|
|
2016*
|
185,630.52
|
735,221.44
|
2,686,763.48
|
1,043,346.61
|
560,838.51
|
5,211,800.56
|
|
Total
|
3,137,689.22
|
8,732,064.66
|
33,618,494.21
|
13,094,086.83
|
7,327,094.30
|
65,909,429.22
|
|
Average
|
348,632.14
|
970,229.41
|
3,735,388.25
|
1,454,898.54
|
814,121.59
|
–
|
*Data from 2016 correspond to the first semester. Source: DATASUS (http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/qiuf.def). Accessed on September 1, 2016.
Regarding health care professional expenses, the Southeast region surpassed the other
regions, with an amount of BRL 2,121,365.37 in 2015, and of BRL 700,318.46 in 2008.
The North region, however, presented lower values compared with the remaining regions,
with BRL 188,139.34 in 2015, and BRL 53,762.80 in 2008. Although the expenses with
the surgical treatment of CSH were higher in the Southeast region, the highest growth
in expenses during the evaluated period occurred at the Northeast region, whose 2015
figures were 4 times higher than those observed in 2008 ([Table 3]).
Table 3
Health care professional expenses (in BRL) for the chronic subdural hematoma surgical
treatment code
|
Region
|
North
|
Northeast
|
Southeast
|
South
|
Central-West
|
Total
|
|
2008
|
53,762.80
|
141,443.90
|
700,318.46
|
247,544.28
|
155,470.16
|
1,298,539.60
|
|
2009
|
97,828.75
|
236,906.46
|
932,017.33
|
316,638.23
|
237,877.98
|
1,821,268.75
|
|
2010
|
131,841.80
|
269,179.70
|
1,134,175.59
|
377,252.52
|
289,015.45
|
2,201,465.06
|
|
2011
|
140,023.38
|
380,987.59
|
1,471,347.18
|
482,553.69
|
358,388.00
|
2,833,299.84
|
|
2012
|
180,931.30
|
492,039.69
|
1,778,718.92
|
548,813.49
|
385,851.03
|
3,386,354.43
|
|
2013
|
196,851.19
|
569,261.68
|
1,825,123.26
|
601,079.45
|
389,804.15
|
3,582,119.73
|
|
2014
|
185,939.20
|
589,062.45
|
1,981,432.59
|
657,176.98
|
452,894.78
|
3,866,506.00
|
|
2015
|
188,139.34
|
648,661.78
|
2,121,365.37
|
600,818.21
|
511,468.30
|
4,070,453.00
|
|
2016*
|
89,461.94
|
312,593.27
|
1,059,720.20
|
350,981.53
|
285,919.86
|
2,098,676.80
|
|
Total
|
1,264,779.70
|
3,640,136.52
|
13,004,218.90
|
4,182,858.38
|
3,066,689.71
|
25,158,683.21
|
|
Average
|
140,531.08
|
404,459.61
|
1,444,913.21
|
464,762.04
|
340,743.30
|
–
|
*Data from 2016 correspond to the first semester. Source: DATASUS (http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/qiuf.def). Accessed on Sep 1, 2016.
Regarding the number of deaths per region, in 2008, the Southeast region presented
the highest number, with 104 cases, followed by the South region, with 43, the Northeast
region, with 31, the Central-West region, with 20, and the North region, with 2 cases.
This proportion was sustained until 2011, when the Northeast region surpassed the
South region, with 53 deaths, while the Southeast region continued to present the
largest number of deaths, 181. From 2014 to 2015, there was a significant increase
in deaths in the Southeast region, with 216 and 218 cases, respectively. It is important
to note that the number of deaths mentioned above did not reflect the mortality rate
from each region ([Table 4]).
Table 4
Number of deaths related to the chronic subdural hematoma surgical treatment code
|
North
|
Northeast
|
Southeast
|
South
|
Central West
|
Total
|
|
2008
|
9
|
31
|
104
|
43
|
20
|
207
|
|
2009
|
14
|
31
|
154
|
44
|
29
|
272
|
|
2010
|
31
|
51
|
151
|
42
|
30
|
305
|
|
2011
|
18
|
53
|
181
|
45
|
39
|
336
|
|
2012
|
21
|
42
|
173
|
46
|
16
|
298
|
|
2013
|
26
|
70
|
174
|
58
|
26
|
354
|
|
2014
|
23
|
65
|
216
|
39
|
28
|
371
|
|
2015
|
21
|
84
|
218
|
60
|
30
|
413
|
|
2016*
|
12
|
36
|
111
|
27
|
16
|
202
|
|
Total
|
175
|
463
|
1,482
|
404
|
234
|
2,758
|
|
Average
|
19.44
|
51.44
|
164.66
|
44.88
|
26
|
–
|
*Data from 2016 correspond to the first semester. Source: DATASUS (http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/qiuf.def). Accessed on September 1, 2016.
Regarding the mortality rate (ratio between the number of deaths and the number of
approved HAAs, computed as admissions during the period, multiplied by 100), the Northeast
region surpassed the other regions in 2008, with 10.73. In 2009, the Southeast came
in first place, with 9.19; and the Northeast had the lowest mortality rate, of 6.47.
The mortality rate has changed in all regions during these years, so that in 2012,
2013, and 2014, the highest rates were observed in the North region, with 10.14, 11.30,
and 10.0, respectively. In 2015, the Northeast region returned to the first place,
with 10.40; in 2016, from January to June, the North region had the highest mortality
rate, with 12.63 ([Table 5]).
Table 5
Mortality rate related to the chronic subdural hematoma surgical treatment code
|
North
|
Northeast
|
Southeast
|
South
|
Central-West
|
Total
|
|
2008
|
8.91
|
10.73
|
8.10
|
10.36
|
6.67
|
44.77
|
|
2009
|
8.28
|
6.47
|
9.19
|
8.54
|
7.20
|
39.68
|
|
2010
|
13.70
|
9.57
|
7.92
|
7.01
|
6.37
|
44.57
|
|
2011
|
9.33
|
8.82
|
8.79
|
7.03
|
7.62
|
41.59
|
|
2012
|
10.14
|
6.51
|
8.13
|
7.15
|
3.31
|
35.24
|
|
2013
|
11.30
|
9.37
|
7.88
|
8.03
|
5.37
|
41.95
|
|
2014
|
10.00
|
8.56
|
9.08
|
5.08
|
5.21
|
37.93
|
|
2015
|
9.86
|
10.40
|
8.58
|
8.50
|
4.85
|
42.19
|
|
2016*
|
12.63
|
8.78
|
8.81
|
6.89
|
5.41
|
42.52
|
|
Total
|
94.15
|
79.21
|
76.48
|
68.59
|
52.01
|
370.44
|
|
Average
|
10.46
|
8.8
|
8.49
|
7.62
|
5.77
|
–
|
*Data from 2016 correspond to the first semester. Source: DATASUS (http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/qiuf.def). Accessed on September 1, 2016.
Discussion
In 1657, Johannes Breakfast Wepfer found a large cyst filled with blood under the
dura mater of a patient who had suffered a stroke. In 1817, Houssard discovered that
the cyst previously described was a membrane-covered clot; the histology and formation
of this lesion were described by Virchow, in 1857, who also called it internal hemorrhagic
pachymeningitis. Next, Trotter defended the theory of trauma in drainage veins for
the superior longitudinal sinus of the subdural hemorrhagic cyst, consolidating its
traumatic etiology in 1914. In 1925, internal hemorrhagic pachymeningitis was renamed
CSH.[1]
[4]
[5]
Subdural hematomas can be classified as acute, subacute and chronic, according to
the time elapsed after the triggering factor. An acute subdural hematoma occurs within
72 hours after the trauma; a subacute hematoma, between 72 hours and 20 days posttrauma;
and a chronic hematoma, 20 days posttrauma. Acute hematomas affect mainly young adults,
whereas chronic hematomas affect the elderly population.[1]
[6]
The risk factors and associated diseases for CSHs include trauma, systemic arterial
hypertension, neurological diseases (cerebrovascular conditions, malformations and
neoplasms), male gender, higher age (> 50 years old), Caucasian ethnicity, alcoholism,
diabetes mellitus, cardiovascular diseases, smoking, cerebrovascular diseases, kidney
diseases, epilepsy, blood dyscrasias, lung diseases, psychiatric history, and positive
human immunodeficiency virus (HIV) serology.[1]
[7]
Epidemiologically, CSH is most commonly found in the 7th decade of life. A male predominance is observed in ∼ 70 to 90% of the cases. Its
incidence has increased worldwide due to the increase in the populational life expectancy;
moreover, it is believed that, in a few years, CSH treatment will be the most performed
neurosurgical procedure, surpassing the resection of primary and metastatic tumors.[2]
[8]
[9]
The pathophysiology of CSH is not fully understood. The main theories regarding its
emergence include the osmotic theory and the recurrent bleeding theory in encapsulated
hematomas. The first one is based on the idea that the liquefaction of the hematoma
increases the osmotic pressure and the protein content, with the consequent attraction
of adjacent fluids to the cavity through a semipermeable membrane. The second theory,
of the recurrent bleeding, is more accepted and states that the blood vessels and
the abnormal capsule of the hematoma are more subject to bleeding. It is noteworthy
that the outer CSH membrane is rich in vessels, with large capillaries, but lacking
smooth muscles in its wall.[7]
[8]
[9] Classically, CSH results from a traumatic lesion of the parasagittal Mittenzweig
vessels. The causes of nontraumatic CSHs include arteriovenous malformations, intracranial
aneurysms, coagulopathies, cerebral convexity tumors, and meningeal carcinomatosis.[1]
[3]
Among the signs and symptoms found in patients with these characteristics, headache
is present in ∼ 80% of the cases, as well as a mentation change that can manifest
itself in different degrees: confusion, somnolence, or coma. These patients may still
present focal neurological deficits, such as hemiparesis (observed in up to 56% of
the cases). Some atypical presentations were cited in selected studies, such as isolated
neurological deficits (vertigo, nystagmus, and oculomotor paralysis), and extrapyramidal
syndromes with a predominance of parkinsonian symptoms.[2]
[7]
[10]
Differential diagnoses include stroke, subarachnoid hemorrhage, and tumors.[2] At a computed tomography (CT) of the skull, CSH presents as a hypodensity. Although
less used, a magnetic resonance imaging (MRI) of the skull can also be requested in
cases in which the CT has some degree of limitation, as in cases of small-volume CSHs.[1]
[7]
[10]
The treatment for CSH may be conservative or surgical. Nonsurgical treatments include
absolute rest, and use of steroids, mannitol, and other hypertonic solutions.[1]
[7] It is worth mentioning that the conservative clinical treatment is not indicated
for most cases, since surgery is aimed at preventing clinical worsening, neurological
deficits, or even death. Currently, the best option is the surgical treatment, which
can often be performed through trepanation or craniotomy, with or without postoperative
drainage placement.[1]
[7]
After the surgery, recurrences are not uncommon; they are related to three factors:
the patient (age, gender, ethnicity, bleeding tendency, and involved comorbidities),
the pathophysiology of the hematoma, and the surgical process. Possible postoperative
complications include acute subdural hematoma, intracranial hypertensive hemorrhage,
and hypertensive pneumocephalus. However, postoperative healing and recovery rates
are high.[1]
[6]
Pereira et al[11] report that the annual incidence of CSH in the general population ranges from 1.72
to 7.35 per 100,000 people, according to aging, with a higher value found in the 8th decade of life. It is estimated that this incidence will continue to grow steadily
as the life expectancy increases.
In Japan, where the elderly population grows faster compared with other countries,
the annual incidence of CSH is 20.6 per 100,000 people, with 76.5 per 100,000 people
in the 8th decade of life, and with 127.1 per 100,000 people in individuals > 80 years old.[12] A study conducted in the United States found an annual incidence rate of 79.6 per
100,000 people in the elderly population. The same study also predicted an increase
in the number of cases by 2030, reaching 121.4 per 100,000 people in this specific
population, and 17.6 per 100,000 people in other age groups, totaling ∼ 60,000 cases
per year in the USA.[13]
There is limited data on the general incidence of CSH in Brazil. However, it can be
inferred from the present paper that, in 2015, the number of hospitalizations due
to CSH corresponded to 0.0023% of the population, or 2.39 hospital admissions per
100,000 inhabitants. It should be remembered, however, that the number of hospitalizations
does not represent a reliable incidence in the country. This bias could be explained
by the noninclusion of selected patients treated in the private health care system.
According to the DATASUS, from 2008 to the 1st semester of 2016, there were 33,878 hospital admissions; the Southeast region had
the highest number of hospital admissions, with 17,442 hospitalizations, and an annual
average number of 2,325.6. The North region had the lowest number of hospital admissions,
1,661, with an annual average of 221.5. Consequently, the Southeast and North regions,
respectively, have the highest and lowest indices of hospital expenses, of health
care professional expenses, and of number of deaths. The mortality rate was not affected
by this rule, since the numbers were higher in the North region.
During the same period, 33,878 CSH-related hospitalizations generated a total hospital
expense of BRL 65,909,429.22, and health care professional expenses of BRL 25,158,683.21.
In the South region, the average hospitalization and health care professional expenses
were of BRL 2,424.83 and BRL 774.61, respectively.
The total number of deaths by CSH during the evaluated period was 2,758, with the
largest number, 1,482, in the Southeast region, followed by 463 in the Northeast region,
404 in the South region, 234 in the Central-West region, and 175 in the North region.
It is worth mentioning that the mortality rate ranged from 6.47 to 12.63 per 100,000
patients during the period studied.
Thus, the obtained data allows inferring that a patient admitted due to CSH generated
hospital expenses of BRL 1,945.50, and professional expenses of BRL 742.62. A hospitalization
day cost BRL 216.16.
During the preparation of the present paper, the noncomprehensiveness of data from
surgeries performed by the private health system and health insurance companies was
considered a limitation, since our purpose was to collect information from procedures
performed by the SUS. In addition, there is a marked scarcity of Brazilian and worldwide
epidemiological contents related to the incidence and prevalence of CSH. Another possible
bias of the present study was the probability of multiple and/or erroneous diagnoses
inclusion in the results found in the DATASUS database.